<p>Nebula Research &amp; Development LLC 在最近向证券交易委员会的披露中表示，在第二季度将其在 Insmed, Inc.（NASDAQ:INSM - 免费报告）股票中的持股比例提高了 985.0%。该机构投资者在本季度额外购买了 33,282 股后，持有该生物制药公司 36,661 股股票。Nebula Research &amp; Development LLC 在 Insmed 的持股在最近的报告期末价值为 3,690,000 美元。</p>
<ul>
<li>罗素重平衡：3 只股票准备上涨</li>
</ul>
<p>其他对冲基金最近也增加或减少了对该公司的持股。挪威银行在第二季度购买了 Insmed 的新股份，价值约为 194,728,000 美元。Adage Capital Partners GP L.L.C. 在第一季度将其在 Insmed 的持股比例提高了 109.2%。Adage Capital Partners GP L.L.C. 目前持有 3,446,944 股该生物制药公司的股票，价值 262,967,000 美元，此前在上个季度额外购买了 1,799,382 股。Nuveen LLC 在第一季度收购了价值约 88,351,000 美元的 Insmed 新股份。Qube Research &amp; Technologies Ltd 在第二季度购买了价值约 108,898,000 美元的 Insmed 新股份。最后，1832 Asset Management L.P. 在第一季度收购了价值约 37,214,000 美元的 Insmed 新股份。</p>
<h2>内部人士下注</h2>
<p>在其他消息中，内部人士 Michael Alexander Smith 于 11 月 3 日星期一出售了 27,130 股 Insmed 股票。该股票以平均价格 183.78 美元出售，总交易额为 4,985,951.40 美元。出售完成后，该内部人士直接持有 54,902 股公司股票，价值 10,089,889.56 美元。此次交易使其持股减少了 33.07%。该出售在向证券交易委员会的备案中披露，您可以通过此链接访问。此外，董事 Melvin Md Sharoky 于 9 月 12 日星期五出售了 10,000 股公司的股票。该股票以平均价格 145.39 美元出售，总价值为 1,453,900.00 美元。交易完成后，该董事持有 262,675 股公司股票，价值约 38,190,318.25 美元。这笔交易使其持股减少了 3.67%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在过去 90 天内共出售了价值 41,063,785 美元的 233,650 股公司股票。3.00% 的股票由公司内部人士持有。</p>
<h2>Insmed 股票表现</h2>
<ul>
<li>股票轮换正在进行：以下是未来的赢家</li>
</ul>
<p>INSM 股票在星期四开盘价为 189.85 美元。该公司的债务与股本比率为 0.59，流动比率为 4.63，速动比率为 4.34。公司的 50 天移动平均价格为 183.45 美元，200 天移动平均价格为 137.61 美元。该公司的市值为 404.9 亿美元，市盈率为 -30.67，贝塔系数为 1.01。Insmed, Inc. 的 12 个月低点为 60.40 美元，12 个月高点为 212.75 美元。</p>
<p>Insmed（NASDAQ:INSM - 获取免费报告）最后一次发布财报是在 10 月 30 日星期四。该生物制药公司报告本季度每股收益（EPS）为 -1.75，低于分析师一致预期的 -1.35，差额为 -0.40。该公司本季度的收入为 1.4234 亿美元，而分析师预期为 1.1433 亿美元。Insmed 的净利润率为 -264.83%，股本回报率为 -183.55%。该公司本季度的收入同比增长 52.4%。在去年同期，该公司每股收益为 -1.27。研究分析师平均预计 Insmed, Inc. 本财年每股收益将为 -4.56。</p>
<h2>分析师升级和降级</h2>
<p>几位股票研究分析师最近对该股票发表了评论。Cantor Fitzgerald 于 10 月 28 日星期二开始覆盖 Insmed 的股票。他们给予该公司 &#34;超配&#34; 评级，目标价为 192.00 美元。加拿大皇家银行在 10 月 31 日星期五将 Insmed 的目标价从 139.00 美元上调至 215.00 美元，并在研究报告中给予该股票 &#34;跑赢大盘&#34; 评级。摩根大通在 8 月 20 日星期三将 Insmed 的目标价从 111.00 美元上调至 135.00 美元，并在研究报告中给予该公司 &#34;超配&#34; 评级。Stifel Nicolaus 在 8 月 14 日星期四将 Insmed 的目标价从 121.00 美元上调至 145.00 美元，并在研究报告中给予该股票 &#34;买入&#34; 评级。最后，TD Cowen 在 11 月 20 日星期四将 Insmed 的目标价从 223.00 美元上调至 231.00 美元，并在报告中给予该公司 &#34;买入&#34; 评级。一位研究分析师对该股票给予了强烈买入评级，二十位分析师给予了买入评级，一位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 &#34;适度买入&#34;，共识目标价为 194.26 美元。</p>
<p><strong>查看我们最新的 Insmed 股票报告</strong></p>
<h2>关于 Insmed</h2>
<p>（免费报告）</p>
<p>Insmed Incorporated 是一家全球生物制药公司，致力于改变严重和罕见疾病患者的生活。Insmed 的首个商业产品是 ARIKAYCE®（阿米卡星脂质体吸入悬液），该产品已在美国获得批准，用于治疗 Mycobacterium avium complex（MAC）肺病，作为针对有限或没有替代治疗选择的成年患者的联合抗菌药物方案的一部分。</p>
<h2>特色故事</h2>
<ul>
<li>我们更看好的五只股票而非 Insmed</li>
<li>内部人士买入解析：投资者需要知道的事项</li>
<li>GameStop 看起来崩溃：为什么 GME 可能在 2026 年崩盘</li>
<li>REIT 股票 - 今天值得加入您投资组合的最佳 REIT 股票</li>
<li>市场动能：3 只有望大幅突破的股票</li>
<li>如何投资保险公司：指南</li>
<li>Casey’s General Stores 将继续上涨的 3 个理由</li>
</ul>
<p><strong>想看看其他对 INSM 感兴趣的对冲基金持有哪些股票？</strong> 请访问 HoldingsChannel.com，获取 Insmed, Inc.（NASDAQ:INSM - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Insmed 吗？</h2>
<p>在您考虑 Insmed 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Insmed 并不在名单上。</p>
<p>虽然 Insmed 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

INSM

<p>Nebula Research & Development LLC 在第二季度将其在 Insmed, Inc. 的持股增加了 985%，目前持有 36,661 股，价值 369 万美元。其他投资者也调整了他们的持仓。尽管第三季度每股收益亏损 1.75 美元，Insmed 的股票表现显示出同比 52.4% 的收入增长。分析师给予了积极的评级，目标价格范围在 135 美元到 215 美元之间</p>

<p>Nebula Research &amp; Development LLC boosted its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 985.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 36,661 shares of the biopharmaceutical company's stock after acquiring an additional 33,282 shares during the quarter. Nebula Research &amp; Development LLC's holdings in Insmed were worth $3,690,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Nebula Research &amp; Development LLC 在最近向证券交易委员会的披露中表示，在第二季度将其在 Insmed, Inc.（NASDAQ:INSM - 免费报告）股票中的持股比例提高了 985.0%。该机构投资者在本季度额外购买了 33,282 股后，持有该生物制药公司 36,661 股股票。Nebula Research &amp; Development LLC 在 Insmed 的持股在最近的报告期末价值为 3,690,000 美元。</p>
</div><ul>
<li>Russell Rebalance: 3 Stocks Ready to Move Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>罗素重平衡：3 只股票准备上涨</li>
</ul>
</div><p>Other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Insmed during the 2nd quarter worth about $194,728,000. Adage Capital Partners GP L.L.C. boosted its position in Insmed by 109.2% during the first quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company's stock worth $262,967,000 after purchasing an additional 1,799,382 shares in the last quarter. Nuveen LLC acquired a new stake in Insmed in the first quarter valued at approximately $88,351,000. Qube Research &amp; Technologies Ltd purchased a new stake in shares of Insmed in the second quarter valued at approximately $108,898,000. Finally, 1832 Asset Management L.P. acquired a new position in shares of Insmed during the 1st quarter worth approximately $37,214,000.</p>
<div class="lb-trans"><p>其他对冲基金最近也增加或减少了对该公司的持股。挪威银行在第二季度购买了 Insmed 的新股份，价值约为 194,728,000 美元。Adage Capital Partners GP L.L.C. 在第一季度将其在 Insmed 的持股比例提高了 109.2%。Adage Capital Partners GP L.L.C. 目前持有 3,446,944 股该生物制药公司的股票，价值 262,967,000 美元，此前在上个季度额外购买了 1,799,382 股。Nuveen LLC 在第一季度收购了价值约 88,351,000 美元的 Insmed 新股份。Qube Research &amp; Technologies Ltd 在第二季度购买了价值约 108,898,000 美元的 Insmed 新股份。最后，1832 Asset Management L.P. 在第一季度收购了价值约 37,214,000 美元的 Insmed 新股份。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, insider Michael Alexander Smith sold 27,130 shares of Insmed stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $183.78, for a total transaction of $4,985,951.40. Following the completion of the sale, the insider directly owned 54,902 shares in the company, valued at $10,089,889.56. The trade was a 33.07% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, Director Melvin Md Sharoky sold 10,000 shares of the firm's stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $145.39, for a total value of $1,453,900.00. Following the transaction, the director owned 262,675 shares in the company, valued at approximately $38,190,318.25. This trade represents a 3.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 233,650 shares of company stock valued at $41,063,785 over the last 90 days. 3.00% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，内部人士 Michael Alexander Smith 于 11 月 3 日星期一出售了 27,130 股 Insmed 股票。该股票以平均价格 183.78 美元出售，总交易额为 4,985,951.40 美元。出售完成后，该内部人士直接持有 54,902 股公司股票，价值 10,089,889.56 美元。此次交易使其持股减少了 33.07%。该出售在向证券交易委员会的备案中披露，您可以通过此链接访问。此外，董事 Melvin Md Sharoky 于 9 月 12 日星期五出售了 10,000 股公司的股票。该股票以平均价格 145.39 美元出售，总价值为 1,453,900.00 美元。交易完成后，该董事持有 262,675 股公司股票，价值约 38,190,318.25 美元。这笔交易使其持股减少了 3.67%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在过去 90 天内共出售了价值 41,063,785 美元的 233,650 股公司股票。3.00% 的股票由公司内部人士持有。</p>
</div><h2>Insmed Stock Performance</h2>
<div class="lb-trans"><h2>Insmed 股票表现</h2>
</div><ul>
<li>Stock Rotation is Underway: Here are the Winners Moving Forward</li>
</ul>
<div class="lb-trans"><ul>
<li>股票轮换正在进行：以下是未来的赢家</li>
</ul>
</div><p>Shares of INSM stock opened at $189.85 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. The company's fifty day moving average price is $183.45 and its two-hundred day moving average price is $137.61. The firm has a market capitalization of $40.49 billion, a P/E ratio of -30.67 and a beta of 1.01. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75.</p>
<div class="lb-trans"><p>INSM 股票在星期四开盘价为 189.85 美元。该公司的债务与股本比率为 0.59，流动比率为 4.63，速动比率为 4.34。公司的 50 天移动平均价格为 183.45 美元，200 天移动平均价格为 137.61 美元。该公司的市值为 404.9 亿美元，市盈率为 -30.67，贝塔系数为 1.01。Insmed, Inc. 的 12 个月低点为 60.40 美元，12 个月高点为 212.75 美元。</p>
</div><p>Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.35) by ($0.40). The firm had revenue of $142.34 million for the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The company's revenue for the quarter was up 52.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.27) earnings per share. On average, research analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Insmed（NASDAQ:INSM - 获取免费报告）最后一次发布财报是在 10 月 30 日星期四。该生物制药公司报告本季度每股收益（EPS）为 -1.75，低于分析师一致预期的 -1.35，差额为 -0.40。该公司本季度的收入为 1.4234 亿美元，而分析师预期为 1.1433 亿美元。Insmed 的净利润率为 -264.83%，股本回报率为 -183.55%。该公司本季度的收入同比增长 52.4%。在去年同期，该公司每股收益为 -1.27。研究分析师平均预计 Insmed, Inc. 本财年每股收益将为 -4.56。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>Several equities research analysts recently commented on the stock. Cantor Fitzgerald began coverage on shares of Insmed in a report on Tuesday, October 28th. They issued an &#34;overweight&#34; rating and a $192.00 price target for the company. Royal Bank Of Canada boosted their price target on shares of Insmed from $139.00 to $215.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, October 31st. JPMorgan Chase &amp; Co. lifted their target price on Insmed from $111.00 to $135.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, August 20th. Stifel Nicolaus upped their target price on shares of Insmed from $121.00 to $145.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, August 14th. Finally, TD Cowen raised their target price on shares of Insmed from $223.00 to $231.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, November 20th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $194.26.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该股票发表了评论。Cantor Fitzgerald 于 10 月 28 日星期二开始覆盖 Insmed 的股票。他们给予该公司 &#34;超配&#34; 评级，目标价为 192.00 美元。加拿大皇家银行在 10 月 31 日星期五将 Insmed 的目标价从 139.00 美元上调至 215.00 美元，并在研究报告中给予该股票 &#34;跑赢大盘&#34; 评级。摩根大通在 8 月 20 日星期三将 Insmed 的目标价从 111.00 美元上调至 135.00 美元，并在研究报告中给予该公司 &#34;超配&#34; 评级。Stifel Nicolaus 在 8 月 14 日星期四将 Insmed 的目标价从 121.00 美元上调至 145.00 美元，并在研究报告中给予该股票 &#34;买入&#34; 评级。最后，TD Cowen 在 11 月 20 日星期四将 Insmed 的目标价从 223.00 美元上调至 231.00 美元，并在报告中给予该公司 &#34;买入&#34; 评级。一位研究分析师对该股票给予了强烈买入评级，二十位分析师给予了买入评级，一位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 &#34;适度买入&#34;，共识目标价为 194.26 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Insmed</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Insmed 股票报告</strong></p>
</div><h2>About Insmed</h2>
<div class="lb-trans"><h2>关于 Insmed</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.</p>
<div class="lb-trans"><p>Insmed Incorporated 是一家全球生物制药公司，致力于改变严重和罕见疾病患者的生活。Insmed 的首个商业产品是 ARIKAYCE®（阿米卡星脂质体吸入悬液），该产品已在美国获得批准，用于治疗 Mycobacterium avium complex（MAC）肺病，作为针对有限或没有替代治疗选择的成年患者的联合抗菌药物方案的一部分。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Insmed</li>
<li>Insider Buying Explained: What Investors Need to Know</li>
<li>GameStop Looks Broken: Here’s Why GME Could Crash in 2026</li>
<li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li>
<li>Market Momentum: 3 Stocks Poised for Major Breakouts</li>
<li>How to Invest in Insurance Companies: A Guide</li>
<li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非 Insmed</li>
<li>内部人士买入解析：投资者需要知道的事项</li>
<li>GameStop 看起来崩溃：为什么 GME 可能在 2026 年崩盘</li>
<li>REIT 股票 - 今天值得加入您投资组合的最佳 REIT 股票</li>
<li>市场动能：3 只有望大幅突破的股票</li>
<li>如何投资保险公司：指南</li>
<li>Casey’s General Stores 将继续上涨的 3 个理由</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding INSM?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 INSM 感兴趣的对冲基金持有哪些股票？</strong> 请访问 HoldingsChannel.com，获取 Insmed, Inc.（NASDAQ:INSM - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=INSM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Insmed Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Insmed 吗？</h2>
</div><p>Before you consider Insmed, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Insmed 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Insmed 并不在名单上。</p>
</div><p>While Insmed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Insmed 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Insmed, Inc. $INSM 的股份被 Nebula Research & Development LLC 收购